153 related articles for article (PubMed ID: 28061543)
1. Transdermal granisetron for the prevention of nausea and vomiting following moderately or highly emetogenic chemotherapy in Chinese patients: a randomized, double-blind, phase III study.
Yang LQ; Sun XC; Qin SK; Chen YX; Zhang HL; Cheng Y; Chen ZD; Shi JH; Wu Q; Bai YX; Han BH; Liu W; Ouyang XN; Liu JW; Zhang ZH; Li YQ; Xu JM; Yu SY
Chin Clin Oncol; 2016 Dec; 5(6):79. PubMed ID: 28061543
[TBL] [Abstract][Full Text] [Related]
2. Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study.
Seol YM; Kim HJ; Choi YJ; Lee EM; Kim YS; Oh SY; Koh SJ; Baek JH; Lee WS; Joo YD; Lee HG; Yun EY; Chung JS
Support Care Cancer; 2016 Feb; 24(2):945-952. PubMed ID: 26265119
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study.
Boccia RV; Gordan LN; Clark G; Howell JD; Grunberg SM;
Support Care Cancer; 2011 Oct; 19(10):1609-17. PubMed ID: 20835873
[TBL] [Abstract][Full Text] [Related]
4. Management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day highly or moderately emetogenic chemotherapy: role of transdermal granisetron.
Coluzzi F; Mattia C
Future Oncol; 2016 Aug; 12(16):1865-76. PubMed ID: 27184113
[TBL] [Abstract][Full Text] [Related]
5. A randomized study of the efficacy and safety of transdermal granisetron in the control of nausea and vomiting induced by moderately emetogenic chemotherapy in Korean patients.
Kim JE; Hong YS; Lee JL; Kim KP; Park SJ; Sym SJ; Shin DB; Lee J; Park YS; Ahn JS; Kim TW
Support Care Cancer; 2015 Jun; 23(6):1769-77. PubMed ID: 25465680
[TBL] [Abstract][Full Text] [Related]
6. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
[TBL] [Abstract][Full Text] [Related]
7. A double-blind, crossover, randomized dose-comparison trial of granisetron for the prevention of acute and delayed nausea and emesis in children receiving moderately emetogenic carboplatin-based chemotherapy.
Berrak SG; Ozdemir N; Bakirci N; Turkkan E; Canpolat C; Beker B; Yoruk A
Support Care Cancer; 2007 Oct; 15(10):1163-8. PubMed ID: 17372773
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of oral granisetron versus oral prochlorperazine in preventing nausea and emesis in patients receiving moderately emetogenic chemotherapy.
Burris H; Hesketh P; Cohn J; Moriconi W; Ryan T; Friedman C; Fitts D
Cancer J Sci Am; 1996; 2(2):85-90. PubMed ID: 9166505
[TBL] [Abstract][Full Text] [Related]
9. A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy.
Ettinger DS; Eisenberg PD; Fitts D; Friedman C; Wilson-Lynch K; Yocom K
Cancer; 1996 Jul; 78(1):144-51. PubMed ID: 8646710
[TBL] [Abstract][Full Text] [Related]
10. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study.
Perez EA; Hesketh P; Sandbach J; Reeves J; Chawla S; Markman M; Hainsworth J; Bushnell W; Friedman C
J Clin Oncol; 1998 Feb; 16(2):754-60. PubMed ID: 9469367
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
Rapoport B; Schwartzberg L; Chasen M; Powers D; Arora S; Navari R; Schnadig I
Eur J Cancer; 2016 Apr; 57():23-30. PubMed ID: 26851398
[TBL] [Abstract][Full Text] [Related]
12. Granisetron Extended-Release Injection: A Review in Chemotherapy-Induced Nausea and Vomiting.
Deeks ED
Drugs; 2016 Dec; 76(18):1779-1786. PubMed ID: 27915445
[TBL] [Abstract][Full Text] [Related]
13. Transdermal granisetron: a guide to its use in preventing nausea and vomiting induced by chemotherapy.
Keating GM; Duggan ST; Curran MP
CNS Drugs; 2012 Sep; 26(9):787-90. PubMed ID: 22834568
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
[TBL] [Abstract][Full Text] [Related]
15. APF530 (granisetron injection extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy.
Schnadig ID; Agajanian R; Dakhil C; Gabrail NY; Smith RE; Taylor C; Wilks ST; Schwartzberg LS; Cooper W; Mosier MC; Payne JY; Klepper MJ; Vacirca JL
Future Oncol; 2016 Jun; 12(12):1469-81. PubMed ID: 26997579
[TBL] [Abstract][Full Text] [Related]
16. Granisetron transdermal system: a new option to help prevent chemotherapy-induced nausea and vomiting.
Schulmeister L
Clin J Oncol Nurs; 2009 Dec; 13(6):711-4. PubMed ID: 19948469
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of the granisetron transdermal system for the control of nausea and vomiting induced by highly emetogenic chemotherapy: a multicenter, randomized, controlled trial.
Sun S; Ko YH; Jin JY; Woo IS; Park SY; Eom YA; Kang JH; Kim HK
Korean J Intern Med; 2023 May; 38(3):406-416. PubMed ID: 35263841
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
[TBL] [Abstract][Full Text] [Related]
19. Transdermal versus oral granisetron in controlling chemotherapy-induced nausea and vomiting: a meta-analysis.
Chua AV; Hernandez ARB; Real IO
Support Care Cancer; 2020 Dec; 28(12):5611-5619. PubMed ID: 32623521
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
Grunberg SM; Rolski J; Strausz J; Aziz Z; Lane S; Russo MW; Wissel P; Guckert M; Wright O; Herrstedt J
Lancet Oncol; 2009 Jun; 10(6):549-58. PubMed ID: 19428297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]